340B Rebate Clash Triggers 5 Suits By Drugmakers
The federal agency overseeing the 340B drug pricing program faces five distinct legal challenges by drugmakers that say the agency illegally blocked their plans to offer rebates rather than upfront discounts...To view the full article, register now.
Already a subscriber? Click here to view full article